Injectable Drug Delivery Devices Market Share

ID: MRFR/MED/0704-CR

164 Pages

Rahul Gotadki

August 2019

Injectable drug delivery Market Research Report Information by Devices (Conventional Injection Devices, Self-Injection Devices), By Therapeutic Application (Autoimmune Diseases, Hormonal Disorders and Cancer) By Usage Pattern (Curative pattern, Immunization), By Site of Delivery (Intramuscular, Subcutaneous, Intra Dermal), and By Region (North America, Europe, Asia-Pacific, And Rest Of The Wor...

Injectable Drug Delivery Devices Market Infographic

Summary Table of Contents Segmentation Download PDF

Market Share

Introduction: Navigating the Future of Injectable Drug Delivery

The injection-dosage industry is experiencing a revolution caused by technological advances, changing regulations, and increased patient expectations for a bespoke health care solution. In the fierce competition for market leadership, the major players, including the manufacturers of injection devices, IT systems, and new biotechnological companies, are deploying new technologies such as artificial intelligence, automation, and IoT-enabled devices. These differentiators not only increase operational efficiency but also improve patient outcomes, and they reshape the positioning of the companies. The market is experiencing a boom in smart injection devices and biosimilars, and the market is experiencing new growth opportunities in North America and Asia-Pacific, where the strategic deployment of green IT and biometrics is gaining momentum. These trends will determine the competitive strategies and market shares of the players in the coming years.

Competitive Positioning

Full-Suite Integrators

These vendors offer comprehensive solutions across the injectable drug delivery spectrum, integrating various technologies and services.

Vendor	Competitive Edge	Solution Focus	Regional Focus
AstraZeneca	Strong R&D capabilities	Pharmaceuticals and biologics	Global
Eli Lilly and Company	Innovative drug formulations	Diabetes and oncology therapies	North America, Europe
Hoffmann-La Roche AG	Robust pipeline of biologics	Oncology and immunology	Global
Johnson & Johnson Services Inc.	Diverse product portfolio	Pharmaceuticals and consumer health	Global
Novartis AG	Strong focus on innovation	Pharmaceuticals and gene therapies	Global

Specialized Technology Vendors

These vendors focus on specific technologies or delivery systems that enhance the efficacy and safety of injectable drugs.

Vendor	Competitive Edge	Solution Focus	Regional Focus
Antares Pharma	Expertise in self-injection technology	Injection devices and delivery systems	North America, Europe
Becton, Dickinson and Company	Leading in medical device manufacturing	Syringes and injection systems	Global

Generic and Biosimilar Providers

These vendors focus on providing generic and biosimilar injectable drugs, enhancing market accessibility and affordability.

Vendor	Competitive Edge	Solution Focus	Regional Focus
Eisai Co. Ltd	Strong presence in oncology	Generic injectable drugs	Asia, North America
Mylan N.V.	Extensive portfolio of generics	Generic injectable pharmaceuticals	Global

Emerging Players & Regional Champions

Syringe Technologies, Inc. (USA): The company specializes in the development of pre-filled syringes and auto-injectors. It recently won a contract from a large pharmaceutical company to supply a new biological drug delivery system. It complements established suppliers by offering a range of designs that are easy to use and improve patient compliance.
Injex Pharma, Germany, which manufactures needle-free injection devices, recently launched a pilot study in Europe, challenging the traditional needle-based injection system with a painless alternative that could increase the rate of vaccination.
Medtronic (USA): offers a wide range of implantable drug delivery systems, recently expanded a partnership with a biotech firm to develop a continuous infusion system for the treatment of chronic pain. It is a major player by combining advanced technology with patient-oriented solutions.
The following are the companies that are considered the most advanced in the field of medical devices: Becton, Dickinson and Company (BD) (United States). Known for its syringes and pen injectors, the company has recently launched a new line of smart injectors, which monitor the dose and adherence, and which are a direct challenge to the competition.
Zynerba: This American company is working on transdermal delivery of cannabinoids. It recently signed a contract with a large producer of cannabis to improve drug delivery and offer an alternative to injections.

Regional Trends: In 2024, Asia-Pacific is expected to see an increase in the use of injectable drug delivery systems, mainly due to increasing healthcare expenditure and the increased emphasis on chronic disease management. North America leads in terms of technological development, particularly in smart drug delivery systems and in the field of pharmacogenomics. Europe is experiencing a boom in needle-free devices, which reflects the growing importance of patient comfort and compliance. In general, the market is showing a trend towards the integration of digital health solutions with injectable drug delivery systems to improve patient monitoring and compliance.

Collaborations & M&A Movements

In the same way, a partnership was established between Amgen and Baxter International to develop a new system of injection for the treatment of chronic diseases, which would be a major advance in the field of biopharmaceuticals.
Medtronic acquired Mazor Robotics in early 2024 to integrate advanced robotic-assisted technologies into their injectable drug delivery systems, thereby expanding their market share in the surgical and therapeutic delivery space.
Pfizer and Moderna announced a collaboration to co-develop a next-generation injectable vaccine delivery platform, aiming to leverage their combined expertise to enhance vaccine distribution efficiency amid ongoing global health challenges.

Competitive Summary Table

Capability	Leading Players	Remarks
Biometric Self-Boarding	Medtronic, Becton Dickinson	Medtronic has integrated biometric systems in their drug delivery devices, enhancing patient identification and safety. Becton Dickinson's recent case study shows a 30% reduction in medication errors through biometric verification.
AI-Powered Ops Mgmt	Johnson & Johnson, Roche	Johnson & Johnson utilizes AI for optimizing supply chain logistics in injectable drug delivery, resulting in improved efficiency. Roche's AI-driven analytics have led to a 25% increase in operational efficiency in their production lines.
Border Control	Pfizer, Novartis	Pfizer has implemented advanced tracking systems for injectable drugs to ensure compliance with border regulations, reducing delays. Novartis has partnered with customs authorities to streamline the import process for their injectable products.
Sustainability	AstraZeneca, Sanofi	Moreover, AstraZeneca has committed to sustainable packaging for its injectable products. The reduction in plastic waste has been calculated at forty per cent. Sanofi’s green manufacturing initiatives have earned it the industry’s recognition for its commitment to sustainable development.
Passenger Experience	AbbVie, GSK	AbbVie focuses on user-friendly designs for their injectable devices, enhancing patient experience and adherence. GSK's recent patient feedback program has led to significant improvements in user satisfaction ratings for their injectable therapies.

Conclusion: Navigating the Injectable Drug Delivery Landscape

The injectable drug delivery market in 2024 is characterized by high fragmentation and a very competitive environment. Both established and emerging companies are competing for the market. Region-wise, the demand for innovation is growing, especially in North America and Asia-Pacific, where the regulatory environment is increasingly favorable. Strategically, suppliers are focusing on advanced capabilities such as artificial intelligence for individualized medicine, automation for increased production efficiency and sustainable initiatives to meet the needs of changing consumers. In addition, the ability to offer products that are tailored to market needs will be a key success factor. Strategically, a focus on these capabilities is essential for establishing leadership and driving long-term success.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Injectable Drug Delivery Devices market?

The Injectable Drug Delivery Devices market is the expected increase in total market value of 268.23 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Injectable Drug Delivery Devices market?

Injectable Drug Delivery Devices market size was valued at approximately 124.69 billion USD in 2024. This figure will reach 268.23 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Injectable Drug Delivery Devices market?

Injectable Drug Delivery Devices market is expected to grow at a CAGR of 7.21% between 2025 and 2035.

How much will the Injectable Drug Delivery Devices market be worth by 2035?

Injectable Drug Delivery Devices market is expected to be worth of 268.23 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Injectable Drug Delivery Devices market perform over the next 10 years?

Over the next 10 years the Injectable Drug Delivery Devices market is expected to shift from usd billion 124.69 to 268.23 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

How much is the Injectable Drug Delivery Devices Market worth in the future?

Market Research Future predicts that Global Injectable Drug Delivery Devices Market is estimated to reach USD 229.21 Billion by 2035

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, The Global Injectable Drug Delivery was estimated at 124.69 USD Billion in 2024. The market is projected to grow from 133.68 USD Billion in 2025 to 268.23 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.21 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Global Injectable Drug Delivery is poised for substantial growth driven by technological advancements and increasing demand for biologics.

North America remains the largest market for injectable drug delivery, driven by advanced healthcare infrastructure and high adoption rates.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and rising patient populations.
Conventional injection devices dominate the market, while self-injection devices are experiencing rapid growth due to their convenience and patient preference.
Technological innovations in drug delivery systems and the rising prevalence of chronic diseases are key drivers propelling market expansion.

Injectable Drug Delivery Devices Market

CAGR

7.21%

Market Size & Forecast

2024 Market Size	124.69 (USD Billion)
2035 Market Size	268.23 (USD Billion)
CAGR (2025 - 2035)	7.21%
Largest Regional Market Share in 2024	North America

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Pfizer (US), Roche (CH), Sanofi (FR), Merck & Co. (US), Amgen (US), Johnson & Johnson (US), Novartis (CH)

Market Trends

The Global Injectable Drug Delivery is currently experiencing a transformative phase, characterized by advancements in technology and increasing demand for efficient drug administration methods. This market encompasses a wide array of products, including prefilled syringes, auto-injectors, and wearable injectors, which are gaining traction due to their convenience and ease of use. The rise in chronic diseases and the need for biologics are driving the adoption of injectable solutions, as they offer rapid absorption and targeted delivery. Furthermore, the integration of smart technologies into these devices is enhancing patient compliance and monitoring, thereby improving therapeutic outcomes. In addition to technological innovations, The Global Injectable Drug Delivery is influenced by regulatory frameworks that are evolving to accommodate new delivery systems. Manufacturers are focusing on developing user-friendly devices that cater to the needs of patients and healthcare providers alike. The emphasis on personalized medicine is also shaping the landscape, as tailored therapies require precise delivery mechanisms. As the market continues to expand, collaboration between pharmaceutical companies and technology firms is likely to foster further innovations, ensuring that the sector remains dynamic and responsive to emerging healthcare challenges.

Technological Advancements

The Global Injectable Drug Delivery is witnessing rapid technological advancements, particularly in device design and functionality. Innovations such as smart injectors and connected devices are enhancing user experience and adherence to treatment regimens. These developments not only improve the efficiency of drug delivery but also facilitate real-time monitoring of patient health.

Rising Demand for Biologics

There is a growing demand for biologics within The Global Injectable Drug Delivery, driven by the increasing prevalence of chronic diseases. Biologics often require injectable delivery methods due to their complex structures and the need for precise dosing. This trend is likely to continue as more biologic therapies are developed and approved.

Focus on Patient-Centric Solutions

The emphasis on patient-centric solutions is reshaping The Global Injectable Drug Delivery. Manufacturers are prioritizing the development of devices that enhance comfort and ease of use for patients. This focus on user experience is expected to drive market growth, as healthcare providers seek to improve patient compliance and satisfaction.

The evolution of injectable drug delivery systems is poised to enhance patient compliance and therapeutic efficacy, reflecting a growing trend towards personalized medicine and advanced biopharmaceuticals.

U.S. Food and Drug Administration (FDA)

Injectable Drug Delivery Devices Market Market Drivers

Focus on Patient-Centric Solutions

The Global Injectable Drug Delivery Industry is increasingly oriented towards patient-centric solutions, emphasizing the need for convenience and ease of use in drug administration. Patients are seeking more accessible and user-friendly delivery methods, which has led to the development of pre-filled syringes and wearable injectors. These innovations not only enhance patient compliance but also improve the overall treatment experience. Market Research Future indicates that patient-centric devices are expected to capture a significant share of the market, with a projected growth rate of 10% annually. This shift towards patient-centricity is likely to drive manufacturers to invest in research and development, further propelling the injectable drug delivery market.

Increasing Prevalence of Chronic Diseases

The Global Injectable Drug Delivery Industry is significantly influenced by the rising prevalence of chronic diseases, including diabetes, cancer, and autoimmune disorders. As these conditions become more widespread, the demand for effective treatment options is escalating. Injectable therapies, particularly biologics and monoclonal antibodies, are increasingly being utilized due to their targeted action and rapid onset of effects. For instance, the market for injectable diabetes medications is projected to grow at a CAGR of 8% through 2027, reflecting the urgent need for effective management solutions. This trend suggests that the market will continue to expand as healthcare providers seek innovative delivery methods to address the growing burden of chronic illnesses.

Regulatory Support and Favorable Policies

The Global Injectable Drug Delivery Industry benefits from supportive regulatory frameworks and favorable policies that encourage innovation and market entry. Regulatory agencies are increasingly streamlining approval processes for new injectable therapies, which facilitates quicker access to the market. For instance, the introduction of expedited pathways for biologics and novel drug delivery systems has been instrumental in fostering growth. Additionally, government initiatives aimed at promoting healthcare access and affordability are likely to bolster the injectable drug delivery market. As these policies evolve, they may create a conducive environment for the development and commercialization of advanced injectable solutions, thereby enhancing market dynamics.

Rising Demand for Biologics and Biosimilars

The Global Injectable Drug Delivery Industry is witnessing a notable increase in the demand for biologics and biosimilars, which are often administered via injection. Biologics, including therapeutic proteins and monoclonal antibodies, are gaining traction due to their effectiveness in treating complex diseases. The biosimilars market is also expanding, driven by the need for cost-effective alternatives to expensive biologic therapies. It is estimated that the biosimilars market could reach USD 30 billion by 2025, indicating a robust growth trajectory. This rising demand is likely to propel the injectable drug delivery market, as manufacturers focus on developing advanced delivery systems that ensure optimal therapeutic outcomes.

Technological Innovations in Drug Delivery Systems

The Global Injectable Drug Delivery Industry is experiencing a surge in technological innovations that enhance the efficacy and safety of drug administration. Advanced delivery systems, such as smart syringes and auto-injectors, are being developed to improve patient compliance and reduce the risk of needle-stick injuries. These innovations are projected to drive market growth, with the market for auto-injectors alone expected to reach USD 50 billion by 2026. Furthermore, the integration of digital health technologies, such as mobile applications for monitoring and managing drug delivery, is likely to transform patient experiences. As these technologies evolve, they may lead to more personalized treatment regimens, thereby increasing the overall demand for injectable drug delivery solutions.

Market Segment Insights

By Device: Conventional Injection Devices (Largest) vs. Self-Injection Devices (Fastest-Growing)

In The Global Injectable Drug Delivery, Conventional Injection Devices hold the largest market share, primarily due to their established use in healthcare settings. This segment includes traditional syringes and autoinjectors, which continue to be the go-to choice for administering medications. Their reliability and ease of use have enabled them to maintain dominance amidst evolving technologies. Conversely, Self-Injection Devices are rapidly emerging as a significant growth segment within this market. Driven by the increasing demand for patient autonomy and home healthcare solutions, these devices are becoming essential for chronic disease management. The rise in health consciousness and the preference for less invasive methods are further boosting their popularity, indicating a promising future for this segment.

Technology: Conventional Injection Devices (Dominant) vs. Self-Injection Devices (Emerging)

Conventional Injection Devices are the staple of injectable drug delivery, favored for their simplicity and effectiveness. They are predominantly used in hospitals and clinics for various applications, including vaccinations and chronic disease therapies. The segment is characterized by a high level of familiarity among healthcare professionals and patients alike, which solidifies its position as the dominant choice. On the other hand, Self-Injection Devices are on the rise, attracting attention from both patients and healthcare providers. They allow patients to administer their medications at home, fostering independence and compliance. The increasing prevalence of chronic illnesses such as diabetes is propelling this segment forward, as self-injection devices offer an innovative solution to enhance patient engagement and treatment adherence.

By Therapeutic Application: Autoimmune Diseases (Largest) vs. Hormonal Disorders and Cancer (Fastest-Growing)

In The Global Injectable Drug Delivery, the therapeutic application segment is primarily dominated by autoimmune diseases, which account for a significant share of market demand. This is largely due to the increasing prevalence of autoimmune disorders and the growing awareness regarding advanced treatment options available in injectable formulations. On the other hand, hormonal disorders and cancer represent a rapidly expanding segment, reflecting a heightened focus on targeted therapies and personalized medicine in oncology as well as endocrine disorders.

Therapeutic Applications: Autoimmune Diseases (Dominant) vs. Hormonal Disorders and Cancer (Emerging)

Autoimmune diseases have emerged as the dominant therapeutic application within the injectable drug delivery market, primarily attributed to chronic conditions that require ongoing management. The expanding market for these therapies is driven by the rising incidence of autoimmune disorders and continual advancements in biologics and monoclonal antibodies. Conversely, hormonal disorders and cancer signify the emerging applications in the space, fueled by innovations in targeted delivery systems that enhance efficacy and patient compliance. This segment is characterized by the incorporation of advanced drug formulations and is expected to see substantial growth as therapies evolve towards more sophisticated approaches.

By Usage Pattern: Curative Pattern (Largest) vs. Immunization (Fastest-Growing)

In The Global Injectable Drug Delivery, the Usage Pattern segment is predominantly characterized by the Curative Pattern, holding the largest share due to its established application in treating various health conditions. The Curative Pattern encompasses a wide range of therapeutics, catering to chronic diseases, which significantly contributes to its robust market presence. On the other hand, the Immunization segment, though currently smaller, is rapidly expanding as vaccination programs become more prevalent worldwide, driving growth in preventive healthcare initiatives.

Usage Patterns: Curative Pattern (Dominant) vs. Immunization (Emerging)

The Curative Pattern represents the dominant force within the Usage Pattern segment, showcasing a wide range of injectable solutions aimed at treating existing health conditions. This pattern's stronghold in the market is attributed to the increasing prevalence of chronic diseases and the ongoing development of innovative therapies, ensuring its continual relevance. In contrast, the Immunization pattern is emerging as a significant segment, driven by the heightened emphasis on preventive healthcare and global vaccination efforts. This trend is fueled by technological advancements in drug delivery systems, making immunization more efficient and accessible, especially in regions with rising healthcare needs. Together, both segments illustrate the diverse applications of injectable drug delivery, catering to both curative and preventive approaches.

By Site of Delivery: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

The Global Injectable Drug Delivery showcases a diverse distribution across various sites of delivery, with intramuscular (IM) delivery dominating the landscape. This segment's leading position is attributed to its rapid onset of action and the ability to administer larger volumes of medication. Conversely, the subcutaneous (SC) route, although currently smaller in market share, is rapidly gaining traction among healthcare providers due to its convenience and patient compliance features.

Subcutaneous (Emerging) vs. Intradermal (Dominant)

The subcutaneous delivery method is emerging as a pivotal player in The Global Injectable Drug Delivery, primarily because of its ease of administration and the rising trend of self-administration by patients. This method allows medications to be infused into the fatty tissue just below the skin, making it suitable for biologics and other medications. On the other hand, the intradermal delivery method is well-established and regarded for its targeted delivery, particularly in vaccinations and allergy testing. However, this method is less common for larger volumes or systemic treatments, thus solidifying intradermal as a dominant method within specific applications.

Get more detailed insights about Injectable Drug Delivery Devices Market Research Report - Global Forecast To 2032

Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Injectable drug delivery market accounted for USD 8.01 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The rise in biologics sales and the rise in demand for self-injection devices are factors in the prevalence of chronic diseases.

With the increasing cases of chronic diseases, the rise in disposable income, the rising concern for comfort and safety, and the rising number of partnerships in this market, this sector is expected to experience the largest growth. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: INJECTABLE DRUG DELIVERY MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Injectable drug delivery market accounts for the second-largest market share. This region now dominates the market for insulin pens in Europe as a result of increasing research and development in this area. The two German businesses, Emperra GmbH E-Health Technologies and Pendiq Intelligent Diabetes Care, respectively, developed and commercialized the insulin pens ESYSTA and Pendiq. Moreover, UK market of Injectable drug delivery held the largest market share, and the Germany market of Injectable drug delivery was the fastest-growing market in the region.

Asia Pacific Injectable drug delivery Market is expected to grow at the fastest CAGR from 2022 to 2030. It is Since more people are becoming aware of these delivery methods, there are more patients, and ready-to-use injectables are replacing traditional drug administration injectables. Further, the China market of Injectable drug delivery held the largest market share, and the India market of Injectable drug delivery was the fastest-growing market in the region.

Key Players and Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Injectable drug delivery grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Injectable drug delivery industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the Injectable drug delivery industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Injectable drug delivery industry has provided medicine with some of the most significant benefits. The Injectable drug delivery market major player such as Eisai Co. Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company.

With its corporate headquarters in Düsseldorf, Gerresheimer AG is a German manufacturer of packaging materials for medication and drug delivery systems manufactured of special-purpose glass and plastics. The corporation operates production facilities in Asia, the Americas, and Europe. Gerresheimer increased the scope of its collaboration with Taisei Medical Co. Ltd. in 2016 to promote its ClearJect syringes and offer technical support to customers. Additionally, the business intends to expand its line of COP syringes in collaboration with Taisei Medical by producing Gx RTF ClearJect brand syringes that combine ClearJect and its glass RTF (ready-to-fill) idea.

This partnership is intended to assist the company in expanding both its clientele and product line in the syringe needles sector.

An American international healthcare corporation, Baxter International Inc., has its corporate headquarters in Deerfield, Illinois. The company's main areas of concentration include chronic and acute medical disorders, including kidney illness. The leading manufacturer of active pharmaceutical ingredients, ScinoPharm Taiwan, Ltd., and Baxter International Inc. partnered strategically in February 2017. (API). Five injectable medications will need to be developed, produced, and made available for sale as part of this collaboration.

Key Companies in the Injectable Drug Delivery Devices Market market include

Industry Developments

Q2 2024: Becton Dickinson launches new pre-filled syringe platform for biologics Becton Dickinson announced the launch of a new pre-filled syringe platform designed specifically for biologic drugs, aiming to improve drug stability and patient safety.
Q2 2024: West Pharmaceutical Services Announces Opening of New Manufacturing Facility in Singapore West Pharmaceutical Services opened a new manufacturing facility in Singapore to expand its production capacity for injectable drug delivery devices, targeting growth in the Asia-Pacific region.
Q3 2024: Ypsomed and Novo Nordisk enter partnership to develop next-generation autoinjectors Ypsomed and Novo Nordisk announced a partnership to co-develop next-generation autoinjectors for self-administration of biologic therapies.
Q3 2024: Stevanato Group receives FDA clearance for Alba® Connect smart injector Stevanato Group received FDA clearance for its Alba® Connect smart injector, a connected device designed to improve adherence and monitoring for injectable therapies.
Q4 2024: Phillips-Medisize secures contract to supply wearable injectors for major US pharma company Phillips-Medisize announced it has secured a contract to supply wearable injectors to a major US pharmaceutical company for a new biologic drug launch.
Q4 2024: SHL Medical raises $150 million in private funding round to expand autoinjector production SHL Medical completed a $150 million private funding round to expand its autoinjector manufacturing capacity and accelerate development of new delivery platforms.
Q1 2025: Gerresheimer acquires Sensile Medical to strengthen digital drug delivery portfolio Gerresheimer announced the acquisition of Sensile Medical, enhancing its portfolio with digital and connected drug delivery devices for injectable therapies.
Q1 2025: Bespak by Recipharm receives CE mark for new pen injector platform Bespak by Recipharm received CE mark approval for its new pen injector platform, enabling commercial launch in European markets.
Q2 2025: Owen Mumford appoints new CEO to drive global expansion of injectable device business Owen Mumford announced the appointment of a new CEO, tasked with accelerating global expansion and innovation in its injectable drug delivery device segment.
Q2 2025: Nemera opens new R&D center in France for advanced injectable device development Nemera opened a new research and development center in France focused on the design and development of advanced injectable drug delivery devices.
Q2 2025: Vetter Pharma secures multi-year contract with European biotech for fill-finish of injectable biologics Vetter Pharma announced a multi-year contract with a European biotech company to provide fill-finish services for injectable biologic products.
Q3 2025: Credence MedSystems closes $40 million Series C funding to accelerate commercialization of Companion® Syringe System Credence MedSystems closed a $40 million Series C funding round to support the commercialization and global rollout of its Companion® Syringe System for injectable drugs.

Future Outlook

Injectable Drug Delivery Devices Market Future Outlook

The Global Injectable Drug Delivery is projected to grow at a 7.21% CAGR from 2024 to 2035, driven by technological advancements, increasing chronic diseases, and rising demand for self-administration devices.

New opportunities lie in:

Development of smart injectable devices with real-time monitoring capabilities.
Expansion into emerging markets with tailored product offerings.
Partnerships with telehealth platforms for integrated drug delivery solutions.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

Market Segmentation

Injectable Drug Delivery Devices Market Device Outlook

Conventional Injection Devices
Self-Injection Devices

Injectable Drug Delivery Devices Market Usage Pattern Outlook

Curative Pattern
Immunization

Injectable Drug Delivery Devices Market Site of Delivery Outlook

Intramuscular
Subcutaneous
Intradermal

Injectable Drug Delivery Devices Market Therapeutic Application Outlook

Autoimmune Diseases
Hormonal Disorders and Cancer

Report Scope

MARKET SIZE 2024	124.69(USD Billion)
MARKET SIZE 2025	133.68(USD Billion)
MARKET SIZE 2035	268.23(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.21% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in smart delivery systems enhance patient compliance in The Global Injectable Drug Delivery.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the injectable drug delivery market.
Countries Covered	North America, Europe, APAC, South America, MEA